SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) (SENECA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04204642|
Recruitment Status : Not yet recruiting
First Posted : December 19, 2019
Last Update Posted : February 12, 2020
Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients. Although increasingly detected, a number of aspects including the pathophysiology, the clinical and neuroradiological phenotype and the disease course are still under investigation. The incomplete knowledge of the disease limits the implementation of evidence based guidelines on patient's clinical management and the development of treatments able to prevent or reduce disease progression.
The SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian multicentre cohort study aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. By a multidisciplinary approach and the collection of a large and well phenotyped series and biorepository of CAA patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA pathophysiological mechanisms.
|Condition or disease||Intervention/treatment|
|Cerebral Amyloid Angiopathy||Other: CAA patients data collection|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA|
|Estimated Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2024|
Cerebral amyloid angiopathy (CAA)
Cerebral amyloid angiopathy (CAA) patients
Other: CAA patients data collection
Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
Other Name: Prognostic factors evaluation
- Clinical and neuroradiological phenotype [ Time Frame: 24 months ]description of the phenotypic characteristics of a large population of CAA patients collected in Italy
- severity of the neuroradiological picture [ Time Frame: 24 months ]Evaluation of the severity of the neuroradiological picture (presence and site of WMHs, CMBs, cSS, CMIs, EPVS ,global cortical atrophy and SAH)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04204642
|Contact: Anna Bersano, MD, Phd||+39022394 ext firstname.lastname@example.org|
|Contact: Renato Mantegazza, MD||+39022394 ext email@example.com|